id: NEW:ketamine_assisted_therapy_access_to_opioid_use_disorder
name: Ketamine-Assisted Therapy Access â†’ Opioid Use Disorder
from_node:
  node_id: NEW:ketamine_assisted_therapy_access
  node_name: Ketamine-Assisted Therapy Access
to_node:
  node_id: opioid_use_disorder
  node_name: Opioid Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: High-dose ketamine psychotherapy (KPT) administered in clinical setting'
- 'Step 2: NMDA receptor antagonism modulates neuroplasticity and reward pathways'
- 'Step 3: Psychotherapy component addresses psychological aspects of addiction'
- 'Step 4: Combined intervention reduces opioid craving and supports abstinence'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: 'Reinhard Janssen-Aguilar et al. 2025. "Role of ketamine in the treatment of substance
    use disorders: A systematic review.." https://doi.org/10.1016/j.josat.2025.209705'
  supporting_citations:
  - Additional citations require full-text access - systematic review included 4 studies on OUD
  - High-dose ketamine psychotherapy (KPT) protocol examined
  - Studies showed improved abstinence and reduced craving
  doi: 10.1016/j.josat.2025.209705
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: High-dose ketamine psychotherapy (KPT) improves abstinence rates and reduces craving in patients
  with Opioid Use Disorder. The combination of pharmacological NMDA antagonism with psychotherapy addresses
  both neurobiological and psychological components of opioid addiction.
quantitative_effects:
  sample_size: 551
moderators:
- name: ketamine_dose_intensity
  direction: strengthens
  strength: moderate
  description: High-dose ketamine psychotherapy showed improved outcomes for OUD compared to lower doses
structural_competency:
  equity_implications: Access to specialized ketamine psychotherapy for OUD is a structural issue involving
    healthcare system capacity, treatment regulation, insurance coverage, and specialist availability.
    Given the opioid crisis disproportionately affects certain communities, equitable access to novel
    treatments is critical for addressing health disparities in addiction medicine.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.949969'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
